Company Overview
Snapshot
Founded in August 2017 by Zeev Dvashi and Abed Elrauf Hijazi, PLAS-FREE operates with 11–50 employees. The company has raised $9.22 million across six funding rounds. In March 2024, PLAS-FREE completed an A Round of funding.
Business overview
PLAS-FREE is an Israel-based company focused on developing advanced blood filtration systems within the Health Tech & Life Sciences sector. Its flagship product, ClearPlasma, is a single-use device designed to extract plasminogen from plasma units, thereby enhancing blood coagulation and promoting hemostasis. The company is also developing the Ammonia Adsorption Column-300 (AAPC-300) to address toxic accumulation in patients with liver failure. PLAS-FREE integrates bio-convergence, combining chemistry, biology, and engineering to deliver innovative medical devices for healthcare providers and hospitals across Asia, Israel, Europe, and the Americas.
Strategic signal
In February 2024, PLAS-FREE was featured in an article by TheMarker, highlighting its life-saving technology. This recognition underscores the company's impact and the strategic importance of its blood filtration systems within the medical device industry, signaling strong market validation and potential for broader adoption.
Log in to access full profile ›Company Intelligence Q&A
- When was PLAS-FREE founded?
- PLAS-FREE was founded in August 2017 by Zeev Dvashi and Abed Elrauf Hijazi.
- What is PLAS-FREE's primary product?
- PLAS-FREE's primary product is ClearPlasma, a single-use device designed to extract plasminogen from plasma units to enhance coagulation and promote hemostasis.
- What was a significant funding event for PLAS-FREE?
- In March 2024, PLAS-FREE secured an A Round of funding. In August 2017, PLAS-FREE received seed funding from NGT3.
- Has PLAS-FREE received any grants?
- In October 2019, PLAS-FREE received a grant from EU Horizon 2020. In December 2021, the company also received a grant from the MedTech Startup Contest.
- What is the Ammonia Adsorption Column-300 (AAPC-300)?
- The Ammonia Adsorption Column-300 (AAPC-300) is a technology under development by PLAS-FREE designed to reduce toxic accumulation in patients with liver failure, currently in pre-clinical trials.